Hypothesis testing outcomes and subsequent analysis

Baseline characteristics

Baseline characteristics: glucose-lowering medications

Baseline characteristics: CV disease

Baseline characteristics: other CV risk factors

Baseline characteristics: CV medication (1/2)

Baseline characteristics: CV medication (2/2)

EMPA-REG OUTCOME

Primary outcome 3P-MACE: time to first occurrence of CV death, non-fatal MI or non-fatal stroke

3P-MACE and 4P-MACE

EMPA-REG OUTCOME

CV death

The effect of empagliflozin on CV death was generally consistent across various subgroup analyses*

EMPA-REG OUTCOME

Hospitalisation for heart failure (HHF)

The effect of empagliflozin on HHF was generally consistent across various subgroup analyses*

EMPA-REG OUTCOME

All-cause mortality

The effect of empagliflozin on all-cause mortality was generally consistent across various subgroup analyses*

EMPA-REG OUTCOME

Kidney outcomes*

Kidney outcomes*

Kidney outcomes* according to baseline eGFR and UACR categories

Mean adjusted eGFR over time

The effect of empagliflozin on kidney outcomes* was generally consistent across various subgroup analyses^†

EMPA-REG OUTCOME: summary

EMPA-REG OUTCOME

Mean adjusted HbA1c

Mean adjusted weight

Mean adjusted BP parameters

Mean adjusted LDL-/HDL-cholesterol

EMPA-REG OUTCOME

EMPA-REG OUTCOME: AEs

Predefined AEs of special interest

Lower limb amputation

EMPA-REG OUTCOME

EMPA-REG OUTCOME: summary

Back-up

Patient disposition and exposure

Categories of CV death

Number needed to treat with empagliflozin added to standard of care to prevent one death in patients with T2D at high CV risk

3P-MACE

3P-MACE: subgroup analysis

CV death: subgroup analysis (1/2)

CV death: subgroup analysis (2/2)

CV death

CV death across types of CV disease present at baseline (1/2)

CV death across types of CV disease present at baseline (2/2)

CV death according to history of atherothrombotic events (prior MI or stroke) at baseline

CV death according to baseline HbA1c

CV death change from baseline in HbA1c at Week 12

CV death according to baseline CV medications

CV death according to baseline glucose-lowering medications

CV death in patients with HF at baseline

The effect of empagliflozin on CV death was consistent across the spectrum of HF risk

CV death in patients with prevalent kidney disease

Time to CV death in patients with prevalent kidney disease

All-cause mortality

All-cause mortality according to history of atherothrombotic events at baseline (MI or stroke)

All-cause mortality according to spectrum of CV risk

All-cause mortality in patients with HF at baseline

All-cause mortality according to kidney function at baseline

Estimated long-term survival

3P-MACE: subgroup analysis in the Asian patient population

CV death: subgroup analysis in the Asian patient population

HHF: subgroup analysis in the Asian patient population

All-cause mortality: subgroup analysis in the Asian patient population

Kidney outcomes: subgroup analysis in the Asian patient population